ALK and non-small cell lung carcinoma: A number of target therapies have shown great antitumor efficiency in the clinic, such as the epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKI) gefitinib and erlotinib for patients with non-small cell lung cancer (NSCLC) harboring sensitizing EGFR mutations [1], crizotinib for patients with NSCLC bearing ALK and ROS1 fusion [1, 2], and Gleevec for patients with gastrointestinal stromal tumor with mutated KIT [3].